
Ligand Pharmaceuticals (LGND) Stock Forecast & Price Target
Ligand Pharmaceuticals (LGND) Analyst Ratings
Bulls say
Ligand Pharmaceuticals is a well-diversified and sustainable company with potential upside from recent acquisitions and partnerships, a focus on sustainability, and a strong human capital management structure. The company has a high-margin operating model, diverse portfolio of royalty-generating assets, and a strategic focus on acquiring royalties for drugs that address unmet medical needs, making it a strong investment opportunity with a target valuation of $252 per share. However, they also face risks such as competition and slow sales, with a downside scenario for their valuation at $98 per share. Overall, Ligand's strong management, diverse portfolio, and potential for future growth make it a positive investment outlook.
Bears say
Ligand Pharmaceuticals is facing challenges with its business model and partnerships. The company's financials are heavily dependent on royalties from commercialized products and license and milestone payments, making it vulnerable to setbacks in its partnerships. The recent approval of FILSPARI for FSGS and potential future revenue may provide a short-term boost, but the company's long-term sustainability is questionable. Additionally, the lack of diversity in the company's board and senior management team raises concerns about its ability to adapt to changing market trends.
This aggregate rating is based on analysts' research of Ligand Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Ligand Pharmaceuticals (LGND) Analyst Forecast & Price Prediction
Start investing in Ligand Pharmaceuticals (LGND)
Order type
Buy in
Order amount
Est. shares
0 shares